In synovial membrane, TA was the only treatment that reduced IL-1β expression significantly (p = 0.011) and trended to reduce the expression of IL-6 (p = 0.402) more effectively than ACS (p = 0.780) or APS (p = 0.601). Here, IL1B is linked to autoimmune polyendocrinopathy.